Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. (PRPO) is a NASDAQ-traded healthcare biotechnology company focused on cancer diagnostics, and its news flow reflects both its operating activities and capital markets developments. The company’s stated mission is to address cancer misdiagnoses through diagnostic products and services that improve accuracy, laboratory workflow, and patient outcomes, and many of its announcements relate to progress toward that mission.
Investors following PRPO news can expect regular updates on the company’s pathology services division and products division. Precipio issues press releases when it files quarterly reports on Form 10-Q, summarizing revenue trends in its diagnostic services and product businesses, gross margin developments, and cash flow metrics. These releases often highlight performance in pathology services and product revenues, along with management commentary on operational efficiency and financial discipline.
Company news also covers product and technology milestones. Precipio has announced developments such as its BCR::ABL1 assay and a joint study with Memorial Sloan Kettering Cancer Center, describing study results, assay performance, and impacts on patient care and laboratory workflows. Additional product-related updates may discuss customer adoption, distributor activity, and the expansion of test panels and applications in customer laboratories.
Capital structure and corporate actions are another recurring theme in PRPO news. The company has issued releases about terminating its at-the-market Sales Agreement with A.G.P./Alliance Global Partners, entering into agreements with warrant holders for cash and cashless exercises, and repaying an advance from Change Healthcare. These updates provide context on share issuance, warrant activity, cash inflows, and the company’s efforts to maintain a clean balance sheet with limited debt.
Precipio also uses news releases to communicate about shareholder update calls, cybersecurity matters, and governance-related events. For example, it has announced quarterly shareholder calls, provided details on a limited-scope unauthorized access incident in its cloud file environment, and requested shareholder participation in voting to achieve quorum at its annual meeting. For investors and analysts, the PRPO news page offers a centralized view of these operational, financial, and corporate developments over time.
Precipio, Inc. (NASDAQ: PRPO) has regained compliance with Nasdaq listing requirements, as confirmed by a letter received on June 29, 2020. The letter noted that the company's shares had maintained a closing bid price at or above $1.00 for ten consecutive business days. CEO Ilan Danieli expressed optimism about future growth opportunities, emphasizing a focus on enhancing shareholder value. Precipio aims to improve diagnostic accuracy through collaborations with leading academic institutions like Yale and Dana-Farber Cancer Institute, supporting patient care worldwide.
Precipio, Inc. (NASDAQ: PRPO) has partnered with Cancer and Hematology Centers of Western Michigan (CHCWM) to implement their HemeScreen technology for molecular testing of hematologic malignancies. This collaboration is expected to generate annual revenues starting at $75,000, potentially doubling with additional assays. The technology allows for faster turnaround times (1-2 days) for crucial test results compared to the industry norm of 2-4 weeks, significantly enhancing patient care. Precipio's Reagent Rental program aims to facilitate molecular testing for physician office laboratories without the need for substantial upfront investment.
Precipio (NASDAQ: PRPO) reported a 77% increase in net revenue for Q1-2020, totaling $1.2M, up from $0.7M in Q4-2019. Key drivers included enhanced sales productivity and internalization of molecular tests. Metrics show a 27% rise in pathology revenue, a 43% increase in case volume, and a 56% growth in new customers compared to the prior quarter. However, average revenue per unit decreased 18% from Q4-2019. Management expresses optimism for continued growth despite challenges posed by COVID-19.
Precipio, Inc. (NASDAQ: PRPO) will host its Quarter 1-2020 corporate update call on May 19, 2020, at 5:00 PM ET. Callers can join by dialing 844-695-5519 or internationally at 1-412-902-6760. Registration is available at here, allowing participants to bypass the operator. Precipio aims to improve diagnostic accuracy through collaborations with leading academic institutions, including Yale and Dana-Farber. The call will address questions submitted via email to investors@precipiodx.com. A replay will be accessible 24 hours post-call on the company's investor page.